ORAI3 and lung adenocarcinoma: Here we evaluated the immunohistochemical expression of Orai3 in a large cohort of lung adenocarcinoma samples (N=200) taking into account their clinic-pathologic features (tobacco exposure, tumour necrosis, visceral pleural invasion, 2011 classification of lung adenocarcinoma and stage), TTF1 expression, tumoural aggressiveness (ERα expression, KRAS and EGFR mutations) and prognostic significance was further evaluated.